IGBA congratulates health Canada for decision on biologics naming that supports growing global consensus

Geneva, 27 February 2019 - The International Generic and Biosimilar medicines Association (IGBA) welcomes Health Canada’s decision  to proceed with a biologic naming policy that identifies all biologic medicines, including biosimilars, by their unique brand name and non-proprietary (common) name, without the addition of a product-specific suffix. Health Canada made the decision following a domestic consultation process with stakeholders.

Read More





We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site